Drug Profile
Ascomycin - Selten Pharma/Vivus
Alternative Names: FK520; SPI 054Latest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator Selten Pharma
- Class Antibacterials; Antifungals; Macrolides
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pulmonary arterial hypertension
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Pulmonary arterial hypertension in USA (unspecified route)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Pulmonary-arterial-hypertension in USA
- 31 Mar 2015 Preclinical trials in Pulmonary arterial hypertension in USA (unspecified route)